About Intersect ENT

Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.

Intersect ENT’s initial focus is on improving the treatment of chronic sinusitis, an inflammatory condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.1,2 Chronic sinusitis often requires a complex combination of medical and surgical therapy and is hence one of the most costly conditions to U.S. employers. While traditional surgical solutions relieve symptoms in many patients, disease recurrence is frequent with the majority of patients experiencing recurrent symptoms within the first year.3

Intersect ENT is a publicly traded company.



We make things happen. Decisive, supportive, trusting, accountable.


We do the right thing. Honest, ethical, thorough.


We assume noble intent. Flexibility, candor, dignity.


We are a team. Diversity of thought, cooperation, partnership, transparency.


We embrace complexity – we figure it out. Undaunted, first in class, transformative.


Thomas A. West

President and Chief Executive Officer


Tom was named Chief Executive Officer and a member of the Board of Directors in July 2019. Previously, he served as Division President, Diagnostics Solutions at Hologic, Inc. At Hologic, he delivered consistent,above-market revenue growth rates in the domestic and international diagnostics business, achieving over $1.1 billion in worldwide diagnostics sales and reversing previous declines. Prior to Hologic, Tom held various roles of increasing responsibility at Johnson & Johnson, including serving as Worldwide Vice President of Strategy and Business Development for Johnson & Johnson’s Diabetes Solutions Companies. He also served as President of LifeScan North America and as President of LifeScan EMEA. Tom earned a Bachelor’s degree in politics and economics from Princeton University and a Master of Business Administration from the Wharton School at the University of Pennsylvania.

Jeryl (Jeri) Hilleman

Chief Financial Officer


Jeri has served as Intersect ENT’s Chief Financial Officer since 2014, just prior to its initial public offering. She brings over 20 years of experience as a CFO, including taking five companies public. Previously, she served as CFO of several public companies including Amyris (NASDAQ: AMRS), a renewable products company, Symyx Technologies (acquired), a materials science research, instrumentation and software company, Ocera (acquired), a biopharma company, and Cytel (acquired), an immunotherapy company. Ms. Hilleman is a member of the Board of Directors and Audit Committees of NovoCure (NASDAQ: NVCR), a commercial global oncology company, and Minerva Neurosciences (NASDAQ: NERV), a biopharma company focused on central nervous system disorders. She served previously as a member of the Board of Directors and Chair of the Audit Committee of Xenoport, Inc. (acquired), a commercial biopharma company. Jeri holds an A.B. from Brown University and an M.B.A. from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

David Lehman

General Counsel


David joined Intersect ENT in 2016 as in-house general counsel. He was previously with Thoratec, a global leader in medical technology addressing advanced-stage heart failure, as Senior Vice President, General Counsel and Secretary prior to Thoratec’s sale to St. Jude Medical in 2015. Prior to that, he served as Vice President and General Counsel at Brigade Corporation, a business process outsourcing company. He previously held positions in the legal departments of Bio-Rad Laboratories, Inc., a life science research and clinical diagnostics company, and Mitsubishi International Corporation, a Japanese trading company, in their New York and Tokyo offices. David began his career as an associate attorney at the law firm of Hall, Dickler, Kent, Friedman & Wood in New York. David holds a B.A. in political science from The University of California, San Diego and a J.D. from Cornell University Law School.

Robert Binney

Chief Commercial Officer


Rob has extensive commercial leadership experience in the medical device and pharmaceutical industries having joined Intersect ENT as Vice President of Sales in 2011, and has built a world-class commercial team serving ear, nose and throat clinicians. Prior to joining Intersect ENT, Rob served as Director of Sales for AccessClosure, Inc., a privately held medical device company where Rob successfully built and led a team of 60 sales professionals, playing a significant role in the organization’s growth from zero to over $70 million. Previously, Rob was a top performing sales professional and trainer at Boston Scientific in the peripheral and vascular surgery markets. He began his medical sales career with Aventis Pharmaceuticals. He holds a B.A. in Communications from the University of North Carolina at Chapel Hill.

Gwen Carscadden

Chief People Officer


Gwen joined the Intersect ENT team in June of 2016 as the company’s Chief People Officer with over 25 years of experience in human resources in both high technology and life sciences sectors. Prior to joining Intersect ENT, Gwen served as Senior Vice President of Human Resources at CardioDx, Inc., a privately held medical diagnostics company. Before that, Gwen held the role of Vice President of Human Resources for Facet Biotech, which was acquired by Abbott in 2010 and served as an Executive Director of Human Resources for PDL Biopharma. She began her career in the technology sector, working for Amdahl Corporation and Fujitsu Computer Systems. Gwen holds an M.A. in Organizational Communication from San Jose State University and a B.A. in Behavioral Sciences also from San Jose State.

Virginia Giddings

Vice President of Research & Development


Virginia joined Intersect ENT in 2019 and serves as Vice President of Research & Development, driving the transformation and expansion of the company’s product portfolio. She has extensive experience in healthcare leadership, with roles in medical device, pharmaceutical and nutrition businesses. Previously she led Advanced Technologies and Innovation and the Program Management Office for Stryker Neurovascular, where she was responsible for delivering the complete product development portfolio as well as key business initiatives and commercial launch management. Prior to Stryker, Virginia ran Strategic R&D for the Nutrition division at Abbott, and played a key role in the development of Abbott’s drug eluting coronary stent and novel bioabsorbable stent. She was responsible for developing IP strategy for drug-device combination products while with ALZA, a Johnson & Johnson Pharmaceutical company. Virginia serves on the Cornell Engineering Council, President’s Council of Cornell Women and Georgia Tech-Emory Bioengineering Board. In addition, she is a Fellow of the American Institute of Medical and Biological Engineering and a co-founder of MedtechWomen, an organization dedicated to highlighting and connecting women leaders in healthcare. Virginia holds B.S. and M.Eng. degrees in Mechanical Engineering from Cornell University, and a Ph.D. in Mechanical Engineering from Stanford University.

Christine Kowalski of Intersect ENT

Christine Kowalski

Chief Operations Officer


Christine joined Intersect ENT in 2018 with more than thirty years of experience in the medical device industry, including nearly two decades in operations and supply chain executive leadership. Christine has held senior executive leadership roles overseeing operations and supply chains for several medical device companies, including ev3 (acquired by Covidien/Medtronic), American Medical Systems/Endo Healthcare Solutions (acquired by Boston Scientific), RTI Surgical, and Johnson & Johnson, where she served most recently as Vice President of Supply Chain Strategy. During her 18 years at Guidant/Boston Scientific, Christine served as Group Vice President of Operations for Vascular Access, Vice President of Global Operations for Vascular Intervention, General Manager of Guidant Puerto Rico’s manufacturing operation, and Vice President of financial audit and reengineering. She earned a bachelor’s degree from the University of North Dakota and a masters in management from Purdue University’s Krannert School of Management.

James Stambaugh

Senior Vice President, Clinical and Medical Affairs


As the company’s second employee, James has led Intersect ENT’s clinical strategy and programs from inception, and his work has helped to ensure patients and physicians have access to the company’s innovative technologies. James has over 20 years’ experience in medical device and pharmaceutical development including regulatory affairs, design and management of human clinical trials, conduct of in-vivo and in-vitro pre-clinical experiments, experience with design controls, design validation, and risk analysis. Prior to joining Intersect ENT, James was Director of Clinical Operations at Guidant’s Vascular Intervention division, responsible for conducting clinical studies for coronary embolic protection, stents, and drug-eluting stents. During his tenure at Guidant, James held various positions within the pre-clinical, clinical and regulatory environment. James started his career as an analytical chemist at an ophthalmic pharmaceutical company, InSite Vision, and later transitioned into clinical research. He holds a B.S. in Chemistry from the University of California at Davis.


Intersect ENT, Inc. declares that, as part of our continued focus on compliance, we have developed a Comprehensive Compliance Program that, to the best of our knowledge and as of the date of this declaration, substantially complies with the requirements of California Health & Safety Code §§ 119400- 119402. Copies of this declaration may be obtained by calling 866-531-6004.  November 1, 2018

1National Health Interview Survey 2006. CDC National Center for Health Statistics. Series 10 Number 235.
2Gliklich et al. Otolaryngol Head Neck Surg. 1995;113:104-9.
3Shaitkin et al. Laryngoscope. 103 Oct 2003.